Ue 0.05 was considered substantial. ACKNOWLEDGMENTS. This study was supported by a Veterans Affairs Merit Award BX000509 and by National Institutes of Wellness Grant HL095686 (to M.R.N.).11. Segal JB, et al. (2001) Coagulation markers predicting cardiac transplant rejection. Transplantation 72(2):23337. 12. Klussmann S, Nolte A, Bald R, Erdmann VA, F ste JP (1996) Mirror-image RNA that binds D-adenosine. Nat Biotechnol 14(9):1112115. 13. Purschke WG, Eulberg D, Buchner K, Vonhoff S, Klussmann S (2006) An L-RNA-based aquaretic agent that inhibits vasopressin in vivo. Proc Natl Acad Sci USA 103(13): 5173178. 14. Darisipudi MN, et al. (2011) Dual blockade in the homeostatic chemokine CXCL12 as well as the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. Am J Pathol 179(1):11624. 15. Vater A, Jarosch F, Buchner K, Klussmann S (2003) Quick bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide quickly identified by a novel approach: tailored-SELEX. Nucleic Acids Res 31(21):e130. 16. Greinacher A, Warkentin TE (2008) The direct thrombin inhibitor hirudin. Thromb Haemost 99(five):81929. 17. Raedler H, et al. (2011) Anti-complement component C5 mAb synergizes with CTLA4Ig to inhibit alloreactive T cells and prolong cardiac allograft survival in mice.Cephalomannine HIF/HIF Prolyl-Hydroxylase Am J Transplant 11(7):1397406. 18. Rothberger H, Barringer M, Meredith J (1984) Improved tissue element activity of monocytes/macrophages isolated from canine renal allografts. Blood 63(three):62328. 19. Lin CC, et al. (2010) Recipient tissue element expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. Am J Transplant ten(7): 1556568. 20. Ji M, et al. (2011) The value of tissue factor expression by porcine NICC in triggering IBMIR within the xenograft setting. Transplantation 91(8):84146.Khan et al.PNAS | April 9, 2013 | vol. 110 | no. 15 |IMMUNOLOGY21. H schermann H, et al. (2000) Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts. Circulation 102(3):35763. 22. Amara U, et al. (2010) Molecular intercommunication in between the complement and coagulation systems. J Immunol 185(9):5628636. 23. Rutkowski MJ, et al. (2010) The complement cascade as a mediator of tissue development and regeneration. Inflamm Res 59(11):89705. 24. Polley MJ, Nachman R (1978) The human complement method in thrombin-mediated platelet function. J Exp Med 147(six):1713726. 25. Wetsel RA, Kolb WP (1983) Expression of C5a-like biological activities by the fifth element of human complement (C5) upon limited digestion with noncomplement enzymes with no release of polypeptide fragments. J Exp Med 157(6):2029048. 26. Krisinger MJ, et al. (2012) Thrombin generates previously unidentified C5 merchandise that support the terminal complement activation pathway.Zaprinast Technical Information Blood 120(8):1717725.PMID:23614016 27. Ward PA, Hill JH (1970) C5 chemotactic fragments developed by an enzyme in lysosomal granules of neutrophils. J Immunol 104(three):53543.28. Huber-Lang M, et al. (2002) Generation of C5a by phagocytic cells. Am J Pathol 161(five): 1849859. 29. Zwirner J, Fayyazi A, G ze O (1999) Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol Immunol 36(134):87784. 30. Allegretti M, et al. (2005) Targeting C5a: Current advances in drug discovery. Curr Med Chem 12(2):21736. 31. Woodruff TM, Nandakumar KS, Tedesco F (2011) Inhibiting the C5-C5a receptor axis. Mol Immunol 48(14):1631642. 32. DiScipio RG, Daffern PJ, Jagels.